Abiopharma

Organon et Samsung Bioepis élargissent leur entente pour la commercialisation de PYZCHIVA® (ustékinumab), un biosimilaire de référence à STELARA® (ustékinumab) au Canada

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

Forrester abre el plazo de presentación de candidaturas para sus 2026 B2B Awards en EMEA

Opening of Trading on June 19 2026-FATTAL HOLD B6

Opening of Trading on June 19 2026-TSG B1

Opening of Trading on June 19 2026-TSG W1

Forrester ouvre l’appel à candidatures pour ses B2B Awards 2026 dans la région EMEA

Sono aperte le candidature di Forrester per i suoi premi B2B 2026 nellarea EMEA

Forrester eröffnet Nominierungsphase für seine B2B-Auszeichnungen 2026 in der EMEA-Region

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement